Diagnosing and managing mild cognitive impairment
- PMID: 29120563
Diagnosing and managing mild cognitive impairment
Abstract
There has been a rapid rise in the number of people diagnosed with dementia in England from 232,000 in 2008 to 850,000 in 2014. Currently, it is estimated that the prevalence of mild cognitive impairment in adults aged 65 and over is 10-20%. It is likely that this figure will increase in line with trends in dementia diagnosis. In some cases, mild cognitive impairment may be a prodrome for dementia, and my be caused by any of the dementia pathology subtypes. The relationship between depression in the elderly and mild cognitive impairment is difficult to tease out as they are frequently comorbid conditions and both have been found to be independent risk factors for subsequent dementia: about 10% convert to dementia each year, compared with 1-2% of the general elderly population. It is important to obtain a history of cognitive changes over time, as well as information about the onset and nature of cognitive symptoms, confirmed by a reliable informant, if available. To confirm the diagnosis objective evidence of cognitive impairment is required. However, there are no specific neuropsychological tests for patients with mild cognitive impairment. On neuropsychological tests, individuals with mild cognitive impairment typically score 1-15 SD below the mean for their age and education, although these ranges are guidelines and not cut-off scores. GPs should consider referring people who signs of mild cognitive impairment for assessment by specialist memory assessment services to aid early identification of dementia, because more than 50% of people with mild cognitive impairment later develop dementia.
Similar articles
-
The clinical utility of naturalistic action test in differentiating mild cognitive impairment from early dementia in memory clinic.Int J Geriatr Psychiatry. 2016 Mar;31(3):309-15. doi: 10.1002/gps.4331. Epub 2015 Aug 11. Int J Geriatr Psychiatry. 2016. PMID: 26264127
-
Optimal cutoff scores for dementia and mild cognitive impairment of the Montreal Cognitive Assessment among elderly and oldest-old Chinese population.J Alzheimers Dis. 2015;43(4):1403-12. doi: 10.3233/JAD-141278. J Alzheimers Dis. 2015. PMID: 25147113
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. PMID: 24354019 Free Books & Documents. Review.
-
Progression from mild cognitive impairment to dementia: a 3-year longitudinal study.Aust N Z J Psychiatry. 2014 Dec;48(12):1137-42. doi: 10.1177/0004867414536237. Epub 2014 May 22. Aust N Z J Psychiatry. 2014. PMID: 24852322
-
[Dementia and mild cognitive impairment in Parkinson's disease: a review].Rev Neurol. 2014 Dec 16;59(12):555-69. Rev Neurol. 2014. PMID: 25501454 Review. Spanish.
Cited by
-
A household survey of the prevalence of subjective cognitive decline and mild cognitive impairment among urban community-dwelling adults aged 30 to 65.Sci Rep. 2024 Apr 2;14(1):7783. doi: 10.1038/s41598-024-58150-3. Sci Rep. 2024. PMID: 38565884 Free PMC article.
-
Role of comprehensive geriatric assessment in screening for mild cognitive disorders.World J Psychiatry. 2023 Jul 19;13(7):478-485. doi: 10.5498/wjp.v13.i7.478. eCollection 2023 Jul 19. World J Psychiatry. 2023. PMID: 37547738 Free PMC article.
-
Automated assessment of speech production and prediction of MCI in older adults.Appl Neuropsychol Adult. 2022 Sep-Oct;29(5):1250-1257. doi: 10.1080/23279095.2020.1864733. Epub 2020 Dec 30. Appl Neuropsychol Adult. 2022. PMID: 33377800 Free PMC article.
-
A pilot feasibility randomized controlled trial on combining mind-body physical exercise, cognitive training, and nurse-led risk factor modification to reduce cognitive decline among older adults with mild cognitive impairment in primary care.PeerJ. 2020 Sep 7;8:e9845. doi: 10.7717/peerj.9845. eCollection 2020. PeerJ. 2020. PMID: 33194354 Free PMC article. Clinical Trial.
-
Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment.Transl Psychiatry. 2020 Apr 29;10(1):125. doi: 10.1038/s41398-020-0801-2. Transl Psychiatry. 2020. PMID: 32350238 Free PMC article.